ライフサイエンスコーパス: topoisomerase I inhibitor

1 al one-pot synthesis of indenoisoquinolines (topoisomerase I inhibitors).

2 ant after treatment with camptothecin, a DNA topoisomerase I inhibitor.

3 its nonthreading counterparts and was not a topoisomerase I inhibitor.

4 t after treatment with topotecan, a specific topoisomerase I inhibitor.

5 s from apoptosis mediated by camptothecin, a topoisomerase I inhibitor.

6 nsitivity to camptothecin, an antineoplastic topoisomerase I inhibitor.

7 the design of future clinical trials of this topoisomerase I inhibitor.

8 Moreover, they acted as topoisomerase I inhibitors.

9 myosin VI transcript were decreased only by topoisomerase I inhibitors.

10 as a strategy for enhancing the efficacy of topoisomerase I inhibitors.

11 AGT inhibitors or O6-alkylating agents with topoisomerase I inhibitors.

12 a novel class of cytotoxic non-camptothecin topoisomerase I inhibitors.

13 glucuronidation in de novo resistance to two topoisomerase I inhibitors.

14 checkpoint also enhanced the cytotoxicity of topoisomerase I inhibitors.

15 1-dihydro-6H-indolo[3,2-c]quinolin-6-ones as topoisomerase-I inhibitors.

16 We show that the topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1

17 RC stress response was also activated by the topoisomerase I inhibitor 7-ethyl-10-hydroxycamptothecin

18 ed prodrug irinotecan (CPT-11) to the potent topoisomerase I inhibitor 7-ethyl-10-hydroxycamptothecin

19 latform, the effect of an apoptotic inducer, topoisomerase I inhibitor, 7-ethyl-10-hydrocamptothecin

20 Time course experiments using the topoisomerase I inhibitor 9-amino-20(S)-camptothecin rev

21 e pancreatic growth factor gastrin), and the topoisomerase I inhibitor 9-nitrocamptothecin.

22 he previously synthesized indenoisoquinoline topoisomerase I inhibitors, a series of compounds lackin

23 circadian toxicity patterns of irinotecan, a topoisomerase I inhibitor active against colorectal canc

24 ]isoquinoline hydrochloride (14) is a strong topoisomerase I inhibitor and also displays very high cy

25 Targeted delivery of a topoisomerase I inhibitor and gapped scheduling allowed

26 applied to the total synthesis of a reported topoisomerase I inhibitor and to the formal synthesis of

27 53-independent channel of cross-talk between topoisomerase I inhibitors and Apo2L/TRAIL and suggest t

28 rtical neurons from mice, we identify twelve topoisomerase I inhibitors and four topoisomerase II inh

29 ibitor of topoisomerase II), camptothecin (a topoisomerase I inhibitor), and ultraviolet radiation in

30 The topoisomerase I inhibitors are a unique class of chemoth

31 Topoisomerase I inhibitors are effective anticancer ther

32 s, which indicates that these two classes of topoisomerase I inhibitors are likely to target the canc

33 olar concentrations of camptothecin (CPT), a topoisomerase I inhibitor, arrest or delay cell cycle pr

34 hydrogen-bonding interactions in determining topoisomerase I inhibitor binding in the ternary cleavag

35 y, markedly enhanced the cytotoxicity of the topoisomerase I inhibitor camptothecin (CPT).

36 atment of HCT116 colon cancer cells with the topoisomerase I inhibitor camptothecin (CPT).

37 Although the topoisomerase I inhibitor camptothecin also activated AT

38 nd PRC2 exhibit synthetic sensitivity to the topoisomerase I inhibitor Camptothecin and accumulate ga

39 A selection protocol using the topoisomerase I inhibitor camptothecin facilitated isola

40 acilitate the cytotoxic effectiveness of the topoisomerase I inhibitor camptothecin in the killing of

41 h clinically-relevant nanomolar doses of the Topoisomerase I inhibitor camptothecin, loss of WRN exon

42 HCT116 human carcinoma cells exposed to the topoisomerase I inhibitor camptothecin, the resulting ga

43 ries, Abbott Park, IL), and the DNA-damaging topoisomerase I inhibitor camptothecin-11 (CPT-11) or SN

44 we examined cells treated with the specific topoisomerase I inhibitor camptothecin.

45 rons undergo apoptosis when treated with the topoisomerase-I inhibitor camptothecin.

46 , we identified DC-stimulatory potentials of topoisomerase I inhibitors (camptothecin derivatives) an

47 various replication inhibitors, including a topoisomerase I inhibitor, camptothecin (CPT).

48 rylated within 1 h after addition of the DNA topoisomerase I inhibitor, camptothecin, and that lamin

49 I inhibitors, etoposide and doxorubicin, and topoisomerase I inhibitor, camptothecin.

50 ensitive PC3 cell line to treatment with the topoisomerase I inhibitor, camptothecin.

51 rationale for combining PARP inhibitors with topoisomerase I inhibitors, clinical use has been hinder

52 erent mass spectrometers: an example using a topoisomerase I inhibitor-conjugated ADC (SCIEX ZenoTOF

53 When combined with the topoisomerase I inhibitor CPT-11 (irinotecan), Apo2L/TRA

54 osure to SN-38, the active metabolite of the topoisomerase I inhibitor, CPT-11.

55 hypothesized that integrating tumor-targeted topoisomerase I inhibitor delivery with optimized PARP i

56 l studies suggest that prolonged infusion of topoisomerase I inhibitors enhances cell toxicity due to

57 The camptothecin (CPT) Top1 (topoisomerase I) inhibitors exert their anticancer activ

58 CPT-11 (Camptosar, irinotecan), a topoisomerase I inhibitor, has been shown to be highly e

59 Two series of indenoisoquinoline topoisomerase I inhibitors have been prepared to investi

60 to determine the antitumor activity of this topoisomerase I inhibitor in 53 patients with metastatic

61 plays a predominant role in the response to topoisomerase I inhibitors in carcinoma cells and identi

62 Indenoisoquinolines are human topoisomerase I inhibitors in clinical testing with impr

63 rgistic with low picomolar concentrations of topoisomerase I inhibitors in improving survival in vivo

64 optotic factors may increase the efficacy of topoisomerase I inhibitors in the clinical setting if gi

65 Camptothecin (CPT), a topoisomerase I inhibitor, induced significantly more ap

66 storation of RAD51 foci in mutant cells when Topoisomerase I inhibitor-induced single strand breaks a

67 owed similar activity to the clinically used topoisomerase I inhibitor irinotecan.

68 This system contains SN-38-a prodrug of the topoisomerase I inhibitor irinotecan.

69 ders tumor cells relatively resistant to the topoisomerase I inhibitor, irinotecan.

70 he biological activity of indenoisoquinoline topoisomerase I inhibitors is significantly enhanced by

71 a liposomal formulation of the water-soluble topoisomerase I inhibitor lurtotecan (GI147211), which d

72 Data for the topoisomerase I inhibitor, luteolin, are presented.

73 eath or apoptosis, we studied campothecin (a topoisomerase I inhibitor)-mediated apoptosis in the hum

74 tically sensitizes glioblastoma cells to DNA topoisomerase I inhibitor-mediated apoptosis.

75 tic effect on how glioblastoma cells process topoisomerase I inhibitor-mediated DNA damage.

76 ne, camptothecin-derived and indolocarbazole topoisomerase I inhibitors, methotrexate, flavopiridol,

77 In comparison, the topoisomerase I inhibitors nitidine and coralyne exhibit

78 expression changes elicited by camptothecin (topoisomerase I inhibitor) or adriamycin (topoisomerase

79 antibody (patritumab) covalently linked to a topoisomerase I inhibitor payload via a stable, tumor-se

80 consisting of a HER3 antibody attached to a topoisomerase I inhibitor payload via a tetrapeptide-bas

81 cted cysteine-conjugated ADC bearing a novel topoisomerase I inhibitor payload, with durable DAR, cur

82 HER2, a novel enzyme-cleavable linker, and a topoisomerase I inhibitor payload.

83 ntibody, cleavable peptide-based linker, and topoisomerase I inhibitor payload.

84 , cleavable peptide-based linker, and potent topoisomerase I inhibitor payload.

85 njugate of humanised anti-HER2 antibody with topoisomerase I inhibitor payloads) in patients with HER

86 Combining XPO1 and topoisomerase I inhibitors reduced DNA damage-induced re

87 iated with POLE mutations and corresponds to topoisomerase I inhibitor resistance, which can be overc

88 amage induced by chemotherapy drugs, such as topoisomerase I inhibitors, results in S and G2 phase ar

89 In vitro data indicate that the addition of topoisomerase I inhibitors shortly after irradiation cau

90 assembly induced by the clinically relevant topoisomerase I inhibitor SN-38, thereby inhibiting the

91 Here we encapsulated the topoisomerase-I inhibitor SN-38 in polymeric nanoparticl

92 ncer drug, and it is a prodrug of the potent topoisomerase I inhibitor, SN-38 (7-ethyl-10-hydroxycamp

93 s activated by esterases to yield the potent topoisomerase I inhibitor, SN-38.

94 y carboxylesterases (CE) to yield the potent topoisomerase I inhibitor, SN-38.

95 The topoisomerase I inhibitor SN38 arrests cell cycle progre

96 t requires the p53 tumor suppressor, yet the topoisomerase I inhibitor SN38 induces p53 after the G(1

97 arrest and enhanced the cytotoxicity of the topoisomerase I inhibitor SN38 only in p53-defective cel

98 efficacy of DNA-damaging agents, such as the topoisomerase I inhibitor SN38, is often compromised by

99 p synthesis of a series of clinically active topoisomerase I inhibitors such as NSC 314622, LMP-400,

100 Measurements with Gyrase and Topoisomerase I inhibitors suggest hindrance to escape s

101 ) mice are hypersensitive to camptothecin, a topoisomerase I inhibitor that causes DNA damage primari

102 anticancer agent camptothecin (CPT) is a DNA topoisomerase I inhibitor that causes fork collapse and

103 Topotecan (TPT) is a topoisomerase I inhibitor that undergoes reversible, pH-

104 isoquinolines are a class of noncamptothecin topoisomerase I inhibitors that display significant cyto

105 indenoisoquinolines are a class of cytotoxic topoisomerase I inhibitors that offer certain advantages

106 Etirinotecan pegol is a long-acting topoisomerase-I inhibitor that prolongs exposure to, but

107 ajority of breast cancers, coupled to SN-38 (topoisomerase I inhibitor) through a proprietary hydroly

108 s synthesized by conjugating camptothecin, a topoisomerase I inhibitor, to our proprietary, 'clickabl

109 egumain-cleavable ADCs that release a potent topoisomerase-I inhibitor (TOP1i) without the need for a

110 reported that combining (131)I-MIBG with the topoisomerase I inhibitor topotecan induced long-term DN

111 A damage induced by gamma-irradiation or the topoisomerase I inhibitor topotecan was used to induce G

112 R-Cas9 screens in cells treated with the DNA topoisomerase I inhibitor topotecan.

113 r treatment with gamma-radiation or with the topoisomerase-I inhibitor topotecan.

114 f bcl-2 family members on the ability of the topoisomerase I inhibitor, topotecan (TPT), to induce pr

115 raction of a PARP inhibitor, ABT-888, with a topoisomerase I inhibitor, topotecan, in PBMCs, tumor, a

116 Camptothecins are potent topoisomerase I inhibitors used to treat high-risk pedia

117 n the present studies, an indenoisoquinoline topoisomerase I inhibitor was conjugated to DUPA via a p

118 Topotecan, a topoisomerase I inhibitor, was evaluated in a multicente

119 Topotecan is a topoisomerase I inhibitor with antitumor activity agains

120 ,2-c]isoquinolines are an important class of topoisomerase I inhibitors with anticancer activity.

121 an pegol (NKTR-102) is a unique, long-acting topoisomerase-I inhibitor with prolonged systemic exposu

122 769962), we combined CRLX101, a nanoparticle topoisomerase I inhibitor, with olaparib using a gapped